Supply of Dolutegravir in China

Partnership objective

Widen access to HIV drugs in China and other developing countries. 

A manufacturing agreement to enable production in China of dolutegravir, active pharmaceutical ingredient in treatments for HIV. A manufacturing agreement to enable production in China of dolutegravir, active pharmaceutical ingredient in treatments for HIV. Copyright ViiV Annual Report

What are the health needs and challenges?

UNAIDS estimates that approximately 780,000 (620,000 to 940,000) people are infected with HIV/AIDS in China.  With more than 40,000 new HIV infections and over 25,000 deaths reported in 2011.  People living with HIV/ AIDS in China who meet the national treatment criteria are referred to receive care through the China National Free Antiretroviral Treatment Programme (CNFATP).  Still, only an estimated 126,000 people with HIV were receiving antiretroviral treatment, with an estimated 76% of adults and children who met the criteria receiving antiretroviral treatment.

Description of partnership activities and how they address needs and challenges

ViiV Healthcare and Desano Pharmaceuticals have begun a manufacturing agreement to enable production in China of dolutegravir, active pharmaceutical ingredient in treatments for HIV. This strengthens ViiV Healthcare’s commitment to improve access to its treatments for people living with HIV, especially in countries hardest hit by the disease.

Under the agreement, Desano will manufacture the API of dolutegravir to feed in to the GSK/ViiV Healthcare supply chain for onward sale in China and developing countries covered by the agreement. ViiV Healthcare and Desano are also exploring further options for future manufacture of finished drug product and fixed dose combinations of dolutegravir with APIs.  

Videos

At ViiV Healthcare We Are All Connected To HIV

Partnership information

Company(ies) GlaxoSmithKline , Pfizer

Partner(s) Desano Pharmaceuticals, ViiV Healthcare

Type of Partner(s) Generic Manufacturers, Other Business

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How

Targeted Population(s) Patients in needs of treatment

Region(s) East Asia & Pacific

Number of Countries 1

Country(ies) China

Start Date 2015

More information ViiV Press Release

Anticipated completion date Ongoing

« We believe that working together with ViiV Healthcare we can better contribute to the global goal of making treatment options available to patients across the globe. »

Ying Kan, President of Desano Pharmaceuticals